论文部分内容阅读
目的评价应用干扰素α-2b与拉米夫定治疗慢性乙型肝炎的疗效及经济学效果。方法 68例慢性乙型肝炎患者随机分为A、B2组,A组(n=38)给予干扰素α-2b(IFNα-2b)500万IU,肌肉注射,隔日1次,疗程1年;B组(n=30)给予拉米夫定100mg,口服,每日1次,疗程2年。运用药物经济学成本—效果分析方法,对干扰素α-2b与拉米夫定治疗慢性乙型肝炎的疗效及成本进行比较。结果 2组药物均能有效治疗慢性乙型肝炎,A组HBeAg转阴率优于B组,A、B组HBV-DNA转阴率比较无显著性差异,成本-效果比分别为119、141。结论干扰素α-2b与拉米夫定均能有效治疗慢性乙型肝炎,但干扰素α-2b成本—效果比优于拉米夫定。
Objective To evaluate the efficacy and economic effect of interferon α-2b and lamivudine in the treatment of chronic hepatitis B patients. Methods Sixty-eight patients with chronic hepatitis B were randomly divided into A and B2 groups. A group (n = 38) received 5 million IU of interferon α-2b (IFNα-2b), intramuscularly and every other day for 1 year. B Group (n = 30) given lamivudine 100mg, orally, once daily, for 2 years. The efficacy and cost of interferon alpha-2b and lamivudine in the treatment of chronic hepatitis B were compared using cost-effectiveness analysis of pharmacoeconomics. Results The two groups of drugs could effectively treat chronic hepatitis B, the negative rate of HBeAg in group A was better than that in group B, and there was no significant difference in the negative rate of HBV-DNA between group A and group B, the cost-effect ratios were 119 and 141 respectively. Conclusion Both interferon α-2b and lamivudine can effectively treat chronic hepatitis B, but the cost-effectiveness ratio of interferon α-2b is better than that of lamivudine.